The role of diet in the management of MAFLD-why does a new disease require a novel,individualized approach?

作     者：Alina Kurylowicz 

作者机构：Department of Human EpigeneticsMossakowski Medical Research CentrePolish Academy of SciencesWarsawPoland Department of General Medicine and Geriatric CardiologyMedical Centre of Postgraduate EducationWarsawPoland 

出 版 物：《Hepatobiliary Surgery and Nutrition》 (肝胆外科与营养（英文）)

年 卷 期：2022年第11卷第3期

页      面：419-421页

核心收录：

学科分类：1004[医学-公共卫生与预防医学(可授医学、理学学位)] 1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：NAFLD arterial MAF 

摘      要：In 2020,international consensus guidelines recommended renaming a non-alcoholic fatty liver disease(NAFLD)to metabolic-associated fatty liver disease(MAFLD)(1).However,these two terms are not *** of MAFLD is established while hepatic steatosis(diagnosed by the use of non-invasive methods as well as liver biopsy)is accompanied by overweight/obesity or type 2 diabetes(T2D)or two or more metabolic risk factors,including increased waist circumference(with cut off values specific for the population),arterial hypertension,hypertriglyceridemia,low high-density lipoprotein cholesterol(HDL-C)(40 mmol/L in women and50 mmol/L in men),prediabetes(impaired fasting glucose,impaired glucose tolerance or glycated hemoglobin 5.7-6.4%).